Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

March 26, 2018

Study Completion Date

April 30, 2018

Conditions
Severe Asthma
Interventions
DRUG

Reslizumab

Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks

Trial Locations (10)

14004

Hospital Reina Sofía, Córdoba

27003

Hospital Universitario Lucus Augusti, Lugo

28046

Hospital Universitario La Paz, Madrid

41013

Hospital Virgen Del Rocío, Seville

46017

Hospital Universitario Dr. Peset, Valencia

48903

Hospital Universitario de Cruces, Barakaldo

48960

Hospital Galdakao-Usansolo, Galdakao

07120

Hospital Universitari Son Espases, Palma

08208

Hospital de Sabadell, Sabadell

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Sociedad Española de Neumología y Cirugía Torácica

OTHER

NCT03074942 - Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab | Biotech Hunter | Biotech Hunter